Department of Dermato-Venereology and Wound Healing Centre, Copenhagen University Hospital Bispebjerg, 2400 Copenhagen, Denmark.
Department of Dermatology and Venereology, Aarhus University Hospital, 8200 Aarhus, Denmark.
Int J Mol Sci. 2023 Jul 11;24(14):11328. doi: 10.3390/ijms241411328.
Chronic urticaria (CU) is a debilitating skin disease affecting around 1% of the population. CU can be subdivided into chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU). Different pathophysiological mechanisms have been proposed to play a role in the development of CU, and these are also being investigated as potential biomarkers in the diagnosis and management of the disease. As of now the only assessment tools available for treatment response are patient reported outcomes (PROs). Although these tools are both validated and widely used, they leave a desire for more objective measurements. A biomarker is a broad subcategory of observations that can be used as an accurate, reproducible, and objective indicator of clinically relevant outcomes. This could be normal biological or pathogenic processes, or a response to an intervention or exposure, e.g., treatment response. Herein we provide an overview of biomarkers for CU, with a focus on prognostic biomarkers for treatment response to omalizumab, thereby potentially aiding physicians in personalizing treatments.
慢性荨麻疹（CU）是一种影响约 1%人群的使人虚弱的皮肤病。CU 可分为慢性自发性荨麻疹（CSU）和慢性诱导性荨麻疹（CIndU）。不同的病理生理学机制被认为在 CU 的发展中起作用，并且这些机制也被作为疾病诊断和管理的潜在生物标志物进行研究。到目前为止，唯一用于评估治疗反应的工具是患者报告的结果（PROs）。尽管这些工具都经过验证并广泛使用，但它们仍然需要更客观的测量方法。生物标志物是一种广泛的观察类别，可以作为临床相关结果的准确、可重复和客观的指标。它可以是正常的生物学或病理学过程，也可以是对干预或暴露的反应，例如治疗反应。本文概述了 CU 的生物标志物，重点介绍了奥马珠单抗治疗反应的预后生物标志物，从而有可能帮助医生个性化治疗。
